PCN45 Analysis of Societal Costs Due to Work Productivity Loss and Activity Impairment from the Monaleesa-7 Trial of Ribociclib + Endocrine Therapy (ET) in Premenopausal Women with HR+/HER2– Advanced Breast Cancer (ABC) in Brazil

Curteis, Tristan; Chandiwana, David; Pathak, Purnima; Lanoue, Brad; Buehler, Anna Maria; Pencheva, Radost; Smith-Tilley, J.

doi:10.1016/j.jval.2021.04.137

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In that study, the same data of MONALEESA-7 trial were used but extrapolated to women at the retirement age of 62 years. Thus, the study showed that ribociclib + endocrine therapy would potentially yield BRL 71.61 million less social costs than endocrine therapy alone 26 .…”

Section: Discussionmentioning

confidence: 97%

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil

et al. 2022

View full text Add to dashboard Cite

OBJETIVE: To evaluate the effect of ribociclib versus endocrine therapy on productivity losses due to advanced breast cancer. METHODS: Productivity data from the MONALEESA-7 trial, obtained from the results of the application of the Work Productivity and Activity Impairment (WPAI) questionnaire on progression-free survival state (43-month follow-up), were extrapolated to the 10,936 Brazilian prevalent cases of premenopausal women with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer. Productivity loss was determined by quantifying the economic costs of workforce dropout over time in both treatment arms and by discounting the economic costs of absenteeism and presenteeism from workforce retention. A human capital approach was used. RESULTS: Net productivity gains in the ribociclib arm were estimated at USD 4,285,525.00, representing 316,609 added work hours over 43 months and a mean of 2,009 added work weeks per year. CONCLUSIONS: The phase III MONALEESA-7 trial productivity results applied to the Brazilian premenopausal prevalent cases of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer showed that treatment with ribociclib + endocrine therapy improves workforce participation compared with endocrine therapy alone in premenopausal women with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer, with potential economic gains for the Brazilian society.

show abstract

Section: Discussionmentioning

confidence: 97%

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil

et al. 2022

View full text Add to dashboard Cite

show abstract

“…For an estimated number of 4294 new cases of premenopausal HR+/HER2− ABC per year, the analyses indicated that women treated with ribociclib plus ET would potentially yield $12.95 million in productivity and activity compared with women treated with ET alone. 41 This study has strengths and limitations. A third party developed the model and performed the analyses, with no interference from the sponsor.…”

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective

Rosa

Magliano²,

Simon

et al. 2022

Ther Adv Med Oncol

View full text Add to dashboard Cite

Introduction: The MONALEESA-7 trial compared ribociclib plus endocrine therapy (ET) with placebo as first-line treatment of advanced luminal/HER2-negative breast cancer (ABC) in premenopausal and perimenopausal women (age <50 years) and showed significant benefits to progression-free survival and overall survival. This study aimed to compare the cost-effectiveness of ribociclib + ET versus ET alone in patients with ABC from the perspective of the Brazilian public national health system. Methods: We calculated the incremental cost-effectiveness ratio (ICER) using a Markov model with progression-free survival, post-progression survival, and death states. We expressed ICER as incremental costs per progression-free life-year (PFLY) and quality-adjusted life-year (QALY) gained in a 10-year time horizon. We used parametric survival distributions fit to MONALEESA-7 data to generate survival distributions for progression-free and post-progression survival. The largest British preference study in breast cancer served as the basis to estimate health-state utilities. We estimated direct costs (ABC treatment, follow-up, monitoring, and adverse events) using Brazilian-specific values from public sources. An expert consensus panel determined the resource patterns required. We applied annual discounts of 5% to costs and QALYs. Results: Ribociclib + ET resulted in an incremental gain of 1.03 PFLYs and 0.80 QALYs at a cost of $37,319.31. The ICER of ribociclib + ET versus ET was $36,379.41 per PFLY gained and $46,590.79 per QALY gained. In deterministic sensitivity analysis, results were primarily affected by the annual discount rate, followed by the cost of ribociclib. In probabilistic sensitivity analysis, simulations agreed with the base-case. Conclusion: Ribociclib increased PFLYs and QALYs in patients with HR+/HER2− ABC when added to ET. Because Brazil does not have a formally defined cost-effectiveness threshold, other domains need to be considered for incorporation decisions, such as disease burden and humanistic impact on this young, economically active population. These findings may be useful in discussions for incorporation of ribociclib into the Brazilian public health system.

show abstract

PCN45 Analysis of Societal Costs Due to Work Productivity Loss and Activity Impairment from the Monaleesa-7 Trial of Ribociclib + Endocrine Therapy (ET) in Premenopausal Women with HR+/HER2– Advanced Breast Cancer (ABC) in Brazil

Cited by 2 publications

References 0 publications

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil

Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective

Contact Info

Product

Resources

About